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ABSTRACT 
Substantial progresses in unraveling the biological fundamentals of Alzheimer disease (AD) 
have occurred over the past decades. However, the early diagnosis of AD, as well as that of many 
other neurodegenerative diseases, remains still challenging. Therefore, the discovery and validation 
of clinically appropriate biomarkers addressing the criteria of specificity, sensitivity, and 
repeatability is eagerly needed.  
Remarkable innovations in the area of high-throughput technologies, such as sequencing, 
microarrays, and mass spectrometry-based analyses of proteins/peptides, have led to the generation 
of large global molecular datasets from a multiplicity of biological systems, such as biological 
fluids, cells, tissues, and organs. Such a methodological progress has shifted the attention to the 
execution of comprehensive analyses, with the aim of fully understanding the biological systems as 
a whole. The systems biology paradigm integrates experimental biology with accurate and rigorous 
computational modelling to describe and foresee the dynamic features of biological systems. The 
use of dynamically evolving technological platforms, including mass spectrometry, in the area of 
proteomics has enabled to rush the process of biomarker discovery and validation for refining 
significantly the diagnosis of AD. Currently, proteomics – which is part of the systems biology 
paradigm – is designated as one of the dominant mature sciences needed for the effective discovery 
of prospective biomarker candidates expected to be of major clinical value in the early diagnosis 
and prognosis of AD.  
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INTRODUCTION 
The most recent years have been characterised by a growing understanding of the molecular 
bases of Alzheimer disease (AD). The pathogenesis of this complex neurodegenerative disorder 
implicates sequentially interacting pathological cascades, including both central events – the 
accumulation of the 42 amino acid-long amyloid β (Aβ1–42) peptide into amyloid plaques and the 
formation of intraneuronal neurofibrillary tangles – and downstream processes – for instance, 
widespread neuroinflammatory reactions. These cellular/molecular events, in the end, cause a 
disintegration of the synaptic structures and induce perturbations of the anatomical and functional 
neural connectivities (1). According to the traditional “amyloid cascade hypothesis”, the clearance 
and degradation of extracellular Aβ play a role of primary importance in the modulation of Aβ 
deposition; therefore, alterations of these processes are considered critical events in the 
pathogenesis of AD (2, 3).  
A plethora of molecular alterations have been observed in the AD brain including, but not 
restricted to, changes in amyloid precursor protein (APP) metabolism (4), tau phosphorylation (5), 
lipid alterations (6), membrane lipid dysregulation (7), mitochondrial dysfunction, amplified 
oxidative stress, activation of neuroinflammatory pathways (8), and anomalous interplay of 
neurotransmitters (9). Given that these perturbations are reciprocally interrelated, a systemic 
approach is necessary in order to shed more light on the pathogenesis of AD at a complex network 
level (10, 11). The aim of the current manuscript is to provide a concise outline of the impact of 
proteomics – as part of the systems biology paradigm – in the context of AD pathophysiology.  
 
NEUROPROTEOMICS AND THE ROLE OF SYSTEMS BIOLOGY TO 
UNDERSTAND ALZHEIMER’S DISEASE MECHANISMS 
Like most neurodegenerative disorders, AD affects not only the neurological system. The 
central nervous system (CNS), encompassing the brain and the spinal cord, plays a role of 
paramount importance in all aspects of life, including some levels of modulation of the activity of 
all other systems in the human body (12). It is recognized that AD patients show physical decline; 
therefore, AD has been evidently associated with systemic manifestations that spread beyond the 
CNS (13). The physical decay is certainly driven to some extent by the progressive functional and 
behavioural failures linked to CNS degeneration (14). Thus, changes in CNS function unavoidably 
result in systemic dysfunction that affects multiple outside organs (12). The high extent of 
heterogeneity in the biological as well as behavioural-clinical genotypes of AD is reflected in the 
extensive variations at the level of neuropathological lesions, age of onset, patterns and types of 
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behavioural-clinical manifestations. These well-validated observations regarding AD emphasize the 
complexity of the multigenic nature of this disorder (15). Conventional biomedical strategies for 
exploring the speculated molecular mechanisms responsible for the pathogenesis of AD have 
commonly been focused on only a few significant genes and their associated products. The final 
outcome of such a line of research has been an insufficient and somewhat reductionistic 
understanding and knowledge of the intricate etiopathogenesis of AD. In contrast, the evolving 
hypothesis-free paradigm of systems biology – also referred to as network biology or integrative 
biology (16, 17) – is an integrative interdisciplinary approach using advances in multimodal high-
throughput technological platforms that enable the examination of networks of biological pathways 
where elevated amounts of structurally/functionally different molecules are simultaneously 
explored over time at a system level (i.e., at the level of cells, tissues, organs, apparatuses, or even 
whole organism) (11). One of the prerequisites of systems biology is the “all-inclusive” 
enumeration and quantification of biological processes, followed by rigorous data inspection and 
integration, in order to allow the generation of hypotheses that need to be confirmed at a system 
level (11). Technologies utilized in systems biology have become relevant and applicable thanks to 
the development of various high-throughput screening strategies applied to the omics sciences. 
Omics disciplines cover genomics/epigenomics, transcriptomics, proteomics, and 
metabolomics/lipidomics. The concrete application of such omics sciences, in conjunction with 
dedicated computational tools, makes unquestionably realistic the full depiction of various 
biomolecules including DNA sequences, transcripts, proteins, metabolites/lipids (18). It should be 
highlighted that, among the rapidly emerging omics disciplines necessary to scrutinize the 
neurodegenerative disorders, with AD being investigated most comprehensively, proteomics has 
undeniably gathered substantial consideration. Proteomics is a rather newly developed area of study 
encompassing the large-scale inspection of protein structures, functions, interactions, and dynamics 
(19). Over the last years, the interest in using proteomics for clinical diagnosis purposes has grown 
exponentially. Actually, clinical proteomics is employed to reveal and/or corroborate novel 
diagnostic and prognostic biomarkers, drug targets, as well as to elucidate novel molecular 
mechanisms (20). Neuroproteomics represents one of the most relevant subcategories of proteomics 
(21). The general aim of clinical neuroproteomics is to explicate the protein-driven biological 
processes and the associated activities at the level of the CNS. As a result, neuroproteomics 
supports the analysis of protein expression and the detection of new original protein/peptide 
biomarkers in order to actively support the diagnosis, treatment monitoring, and prognosis of CNS 
pathologies (19). The depiction of the CNS proteome under both healthy and pathological 
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conditions is fully supported by the Human Proteome Organization (HUPO, available at 
http://www.hupo.org/), the largest global consortium that is committed to facilitate proteomic 
exploration bodily fluids and human tissues. Interestingly, the HUPO Brain Proteome Project 
(HUPO BPP, available at http://www.hbpp.org/), an open international project under the patronage 
of the HUPO, aims at explicating the CNS proteome in both aging and neurodegenerative disorders, 
including AD (22).  
 
BIOMARKER EVIDENCE OF ALZHEIMER’S DISEASE PATHOLOGY 
Remarkable methodological progress has led to a multimodal framework of AD biomarkers, 
including both biochemical and imaging markers (15, 23-26). Existing biomarkers of AD result 
from neurogenetics (27-29), structural/functional/metabolic neuroimaging and neurophysiology (30, 
31), neurobiochemistry on biological fluids (32, 33), including both cerebrospinal fluid (CSF) (34-
37) and blood (plasma/serum) (38-42). However, the diagnostic power of such a multimodal 
approach to AD diagnosis is yet to be established and needs to be additionally validated in terms of 
sensitivity, specificity, and predictive power (43-46). To this aim, substantial efforts among 
biotechnology, pharmaceutical and regulatory stakeholders, clinicians, researchers, and health care 
decision makers are eagerly required (47, 48). For a biomarker to mature to a validated and 
standardized clinical test, it should be feasible, reproducible, and fully available with quality 
control. Currently, the best established fluid biomarkers for AD include three core CSF molecules: 
Aβ1–42 (that reflects Aβ plaque formation in the brain), phospho-tau (P-tau; that mirrors 
neurofibrillary tangle pathology in AD), and total-tau (T-tau; a marker of axonal degeneration) 
markers. All of these biomarkers have been validated against pathology and have 85-95% 
sensitivity and specificity for AD in both dementia and prodromal mild cognitive impairment (MCI) 
stages (35). At present, the amyloid cascade hypothesis, where aggregated forms of Aβ – especially 
soluble and diffusible Aβ oligomers – have been assumed to have a key role in AD pathogenesis, is 
highly relevant (2). However, the hypothesis has been challenged by failures of some recent phase 
III clinical trials aimed at blocking Aβ production, by using secretase inhibitors (49), or enhancing 
its clearance from the brain, by employing anti-Aβ immunotherapy (50, 51). As a result, such 
ineffective clinical trials of Aβ-targeting drug candidates have raised the idea that additional 
pathological pathways may be involved in the clinical expression of AD (52). In order to acquire 
more knowledge about the pathophysiology of AD, searching for unique and original biomarkers 
for potential disease-related molecular alterations is of great significance. A significant effective 
system for detecting these biological markers is via proteomic investigations (53).  
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OVERVIEW OF TECHNOLOGIES FOR NEUROPROTEOMIC ANALYSIS 
Over the last 30 years, numerous technological platforms have been employed in 
neuroproteomics to scrutinize different biological samples collected from patients with different 
neurodegenerative disorders. Several steps characterize the workflow of a typical proteomic 
investigation, including: sample preparation; protein separation, identification and quantification; 
protein biomarker candidates validation (see Schevchenko and colleagues (2015) for a detailed 
methodological overview) (19). In particular, currently acknowledged proteomic methods include a 
sequence of separation, enzymatic digestion (often in conjunction with some kind of isotopic 
labelling) and mass spectrometric analysis. The step of protein separation is commonly performed 
by using two-dimensional polyacrylamide gel electrophoresis (2-DE), liquid chromatography (LC), 
or protein-chip arrays. The protein content of the sample is then subjected to tryptic (or another 
enzyme) digestion to generate peptides that are amenable to analysis by mass spectrometry (MS) or 
tandem mass spectrometry (MS/MS) (54). Notably, MS is considered a key technology for the 
systemic examination of proteins, i.e., from identification and quantification to characterization of 
post-translational modifications and protein-protein interactions. All mass spectrometers, regardless 
of type, ionization mode, or performance details, generate mass spectra, which plot the mass-to-
charge ratio (m/z) of the detected ions versus ion abundance. The identification step is performed by 
correlating the experimentally discovered molecular masses with known protein/peptide masses via 
database search algorithms (19). However, whether a protein/peptide has been identified, what 
confers it the status of a candidate marker is its consistent variation in some characteristic such as 
abundance between two states, for instance, presence or absence of a given disease (15).  
In recent times, there has been a remarkable development of methodologies and 
instrumentation for protein/peptide quantification including label-based and label-free technologies.  
A number of quantitative MS-based methods have been applied to neuroproteomics studies, such as 
traditional approaches – 2-DE and differential two-dimensional gel electrophoresis (2D-DIGE) – as 
well as more innovative quantitative systems, for instance: isotopic chemical labelling, label-free 
quantification methodologies, and selected reaction monitoring (SRM) (19). The labelled 
approaches – for instance, isobaric tags for relative and absolute quantitation (iTRAQ) (55), stable 
isotope labelling by amino acids in cell culture (SILAC) (56) and tandem mass tag (TMT) multiplex 
isobaric labelling (ref: Hölttä M et al., J Proteome Res. 2015 Feb 6;14(2):654-63) – display a 
substantial decrease in operation-related sample-to-sample variations since all samples are mixed 
and processed simultaneously after being labelled with different tags. The quantity of specimens 
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utilized in a single experiment is determined by the availability of tags (12). Differently from the 
labelled approaches, the label-free methods have the advantage of using protein quantification 
without needing any isotope labelling. Consequently, these methods are not laborious and can be 
applied to all biological samples (19). Label-free methods offer more flexibility regarding the 
amount of samples to be used in an experiment and need less hands-on operation. However, these 
approaches necessitate more computation time for data analysis and higher consistency from sample 
preparation. Furthermore, a stable mass spectrometer is needed because they are reliant on data 
comparison from independent MS runs (12). Notably, SRM is an MS-based, targeted protein 
measurement to identify relative and absolute peptide levels (57). In contrast to global protein 
profiling approaches, SRM enables the detection of well-defined target peptides with both high 
selectivity and sensitivity to measure low abundant proteins in complex specimens in relation to 
labelled standard peptides (19). The major benefits of the SRM compared to the conventional 
enzyme-linked immunosorbent assay (ELISA) are the substantially shorter lead-time and decreased 
costs and that the method does not rely on the optimal interaction of the target analyte with 
antibodies. Whereas the optimization of a single ELISA assay may take over 1 year, the 
development of a SRM assay may occur within weeks and allows multiplexing of assays for 
numerous biomarkers at the same time (58). As a result, SRM is considered a novel ground-
breaking method to complement the traditional immunoassays, like ELISA, as a diagnostic tool in 
clinical practice (19). Definitively, quantitative neuroproteomics is a discipline commonly utilized 
to measure the relative and absolute protein abundance between two or more conditions (for 
example, healthy versus diseased or treated versus placebo) with the aim of investigating significant 
alterations in the proteome and disclosing novel protein biomarkers. 
These neuroproteomic tools are now being combined to establish robust platforms for further 
improving quantitative, high-throughput proteomics. This effort is supported by the constant 
introduction of novel high-performance mass spectrometers. Actually, specialized laboratories with 
MS facilities can identify and quantify hundreds of proteins per day on a single MS system; thus, 
rapid advances in sample throughput, sensitivity, and accuracy are anticipated to occur (16, 17). In 
summary, the evolving area of neuroproteomics needs to address the issues of the heterogeneity and 
complexity of the CNS, both at cellular and subcellular level. However, if suitable sample 
preparation and separation procedures are executed, neuroproteomics tools utilizing MS are 
expected to provide clinically relevant data on biological fluids. These include proteins/peptides 
identification, characterization, and significant alterations in their relative/absolute amount 
according to the pathological conditions (19, 21).  
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One of the most important benefits of employing proteomics consists of the simultaneous 
characterization and quantification of hundreds or even thousands of proteins (59). Both explorative 
and targeted proteomic strategies have been performed to reveal major quantitative discrepancies in 
terms of protein expression among AD patients, patients with other non-AD associated disorders, 
and healthy individuals. Explorative proteomic studies aim at exploiting technological platforms on 
clinical samples – body fluids, tissues, definite groups of cells – in order to recognize distinctive 
biomarkers and, accordingly, characteristic pathological signatures that can facilitate the 
comprehension of the mechanisms responsible for the advancement of the disease. Therefore, the 
knowledge about the pathology will be also enriched. Differently, targeted proteomics studies are 
focused on the examination of one protein (and its altered forms), or a precise group of 
proteins/peptides that are exposed to proteomic investigation. In this setting, proteomic methods in 
cooperation with immunopurification and immunoprecipitation protocols are frequently employed. 
According to Brinkmalm and colleagues (2015), such a methodological strategy preserves the 
capacity and specificity of proteomic approaches and often results in higher analytical sensitivity 
(53).  
 
LIMITATIONS OF NEUROPROTEOMICS 
The variations of the proteome in AD have been scrutinized at different stages of the disease 
using a plethora of high-throughput systems. Different technological platforms have been utilized 
both in CSF (60–81) and blood (i.e., plasma/serum) (82–97). The most recent data in terms of 
applications of proteomics in the field of AD – both in CSF and blood specimens – are 
comprehensively reported by Brinkmalm and colleagues (2015) (53), Lista and colleagues (2015) 
(23), and Rosén and colleagues (2013) (32).  
CSF is produced by filtration of blood in the choroid plexus and by diffusion from the 
extracellular matrix of the brain into the ventricles (98). CSF generation occurs at a rate of 500 
mL/day and turns over about 4 times per day by drainage into the blood (99). It surrounds both the 
brain and the spinal cord and constantly receives a stream of proteins from the brain; indeed, nearly 
20% of the amount of proteins in the CSF are known to originate from the brain (100). Given its 
contiguity to the diseased brain tissue and its anatomical interaction with the brain interstitial fluid, 
where neurochemical alterations associated to CNS pathologies are reflected, CSF is an invaluable 
source of protein/peptide biomarkers that supports the diagnosis of neurodegenerative disorders and 
can aid in monitoring their progression (101). In addition to intact proteins, CSF presents a large 
number of endogenous peptides (102) which are created by specific enzymatic reactions, while 
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others are generated by common degradation pathways. These peptides mirror a multitude of 
mechanisms in the brain, such as processes of secretion and aggregation as well as enzymatic 
activities and tissue re- and degeneration. For this reason, the investigation of the CSF is of high 
relevance to get more in detail into the pathology of CNS disorders. Nevertheless, the main 
drawback limiting the clinical application of the CSF is the invasive nature of the procedure for its 
collection: lumbar puncture, colloquially known as a spinal tap, is still considered in many countries 
a quite intrusive practice that may cause patient discomfort and displays side effects as the post-
lumbar puncture headache (103). Even though there are studies demonstrating the low incidence of 
lumbar puncture-associated headaches and almost no additional clinical complications in a memory 
clinic setting (104), CSF sampling still suffers from a negative public reputation together with high 
rates of reservation among patients (105). Furthermore, the collection of CSF from healthy 
individuals is still an ethical concern.  
Blood is considered a complex liquid tissue that includes cells and extracellular fluid. It can 
be divided into two compartments: plasma, i.e. the cell-free content of the blood, and the blood 
cells. Serum is blood that has been allowed to clot, removing cells and coagulation factors (i.e., 
plasma without coagulation factors). Potentially, blood is a rich source of biomarkers since proteins, 
nucleic acids, lipids, as well as other metabolic products can be detected in plasma, serum, and 
cellular compartments. The cellular fraction of blood includes erythrocytes, leukocytes, and 
platelets, which can be separated either crude, for instance via buffy coat after density gradient 
centrifugation, or isolated by flow cytometry into distinct cell clusters. The diversity of potential 
candidate biomarkers in blood is substantial and may embrace: proteins (in terms of their 
concentration, isoforms, and post-translational modifications); metabolic products subject to 
considerable alterations; nucleic acids (DNA and RNA). All these aspects emphasize that, unlike 
CSF and other body fluids, blood is quite a multifaceted tissue (106).   
It should be highlighted that the search for protein biomarkers in blood present some 
challenges (107). Even though the high complexity of blood – as element reproducing the condition 
of the whole organism – may be considered a benefit, it may be also seen as a restriction. A first 
limitation, from a methodological viewpoint, is given by the high diversity of proteins and peptides. 
Alternative splicing mechanisms, conformational changes, and post-translational modifications 
allow proteins to appear in various forms, thus impressively increasing the heterogeneity of the 
plasma/serum proteome (108). A second restriction is represented by the large concentration range 
of plasma/serum proteins encompassing 1011 - 1012 orders of magnitude, from mg/mL to pg/mL 
(108). Third, around 90% of the content of total plasma/serum proteins belongs to one of the ten 
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major groups of the high-abundance proteins (HAPs): albumin (covering alone approximately 
50%), immunoglobulins, transferrin, fibrinogen, α-2 macroglobulin, α-1 antitrypsin, C3-
complement factor, and haptoglobin (107). These proteins are supposed not to be adequately 
“informative”; therefore, they cannot be exploited as disease biomarkers (109). The residual 10% is 
a complex mixture of middle- and low-abundance proteins (MAPs and LAPs); the tens of thousands 
of LAPs, assumed to be clinically significant and, thus, to denote potential biomarkers, are 
“masked” under few non-informative HAPs and referred to as the “hidden” proteome (110). The 
content of LAPs is many orders of magnitude inferior to that of HAPs. Usually, biological markers 
for malignant or non-malignant pathologies cover a range of concentrations from ng/mL to pg/mL 
(111). As a result, methods for separating and/or removing HAPs seem to have a key role to limit 
such a dynamic range and identify/quantify the majority of protein species in a sample. Overall, 
because of the wide concentration range and the well-known complexity of proteins (compared to 
other types of biological molecules), all proteomic technologies presently implemented are 
scrutinizing only a minor fraction of potential biomarker-relevant changes that can be detected in 
pathological conditions (106).  
Similar to omics projects performed on other body fluid, plasma/serum proteomics displays 
various methodological issues, such as preanalytical variables, the need for standardizing specimen 
collection/processing, quantitation, and strategies on how to deal with biomarkers once they have 
been detected (107). Advancement in blood biomarker discovery is also based on the development 
of standard operating procedures (SOPs) for the suitable selection of patients and specimens to 
diminish the complexity of samples intended to be examined (112). Global initiatives such as the 
Human Plasma Proteome Project (HPPP) (available at http://www.hupo.org/initiatives/plasma-
proteome-project/), as part of the Human Proteome Organization (HUPO) (available at 
http://www.hupo.org/), have been established to address matters associated with preanalytical 
variability and to initiate the process of drafting SOPs (113). Furthermore, there is ongoing progress 
in the development of informatic tools for data management as well as collaborations with other 
disease-related initiatives of the HUPO to expand the area of plasma/serum biomarker discovery 
(114). Additionally, an international collaboration for the initiation of preanalytical guidelines for 
AD blood-based biomarkers is underway as part of the Alzheimer’s Association Professional 
Interest Area (PIA) on Blood Based Biomarkers (BBB-PIA) (39). The BBB-PIA is a part of the 
Alzheimer’s Association’s International Society to Advance Alzheimer’s Research and Treatment 
(ISTAART), that has been established in order to develop a field-wide consensus on the 
harmonization of both preanalytical and analytical protocols and to address the requirement of a 
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biorepository of clinical reference samples, thus enabling not only assay harmonization but also 
clinical performance assessment (40). Finally, it should be also highlighted that preanalytical 
procedures are also provided by the Clinical and Laboratory Standards Institute (CLSI, available at 
http://clsi.org/) that represents a guiding source for individuals seeking to take research-derived 
techniques to clinic.  
 
CONCLUSIONS  
The working hypothesis of AD is that all forms of this pathology advance through the 
emergence and, at some time, convergence of failures in several systems, networks, signalling 
pathways, and the appearance of pathophysiological processes such as neuroinflammation, 
perturbed lipid homeostasis, apoptosis, oxidative stress, tau hyperphosphorylation with subsequent 
neurofibrillary tangles formation, and the amyloidogenic cascade leading to the production and 
release of different Aβ peptides. In the post-genomic era, the understanding of biological systems is 
dynamically evolving and progressing. Genomic research advanced to proteomics and led to a 
deeper knowledge of the structure and function of proteins. Proteomics is indeed considered one of 
the fastest developing disciplines enabling the fully elucidation of the crucial processes in growing, 
differentiation, and regulation occurring at various stages at cellular and intercellular levels. 
Proteomics has then given birth to the discipline of neuroproteomics as the aspects of neurological 
disorders – which appeared to be yet unclear less than a generation ago – commenced to be 
unveiled. Because of the highly degree of heterogeneity and inaccessibility of the human brain, 
neuroproteomics studies in humans have addressed biological fluids, mainly CSF and blood. CSF, 
in particular, is a highly relevant biological fluid for biomarker discovery as it is in close contact 
with the brain. From a basic research perspective, the development of proteomics – as well as the 
interrelated omics sciences, namely genomics/epigenomics, transcriptomics, 
metabolomics/lipidomics – has revealed the approach for the identification of novel molecular 
biomarkers from biofluids (besides cells, group of cells, and tissues). High-throughput molecular 
profiling approaches have the ability to accumulate large amounts of data concerning a given 
disease status or a specific phenotype, in an unbiased way (15). The close relationships among the 
various omics platforms are crucial to developing a clinically operative AD biomarker panel: such a 
multi-omic interdisciplinary system is anticipated to considerably advance the biomarker discovery 
area (41). Omics strategies, in combination with bioinformatics, including computational and 
statistical modelling, support and simplify the identification/characterization of DNA/RNA 
sequences, transcripts, proteins/peptides, metabolites/lipids, and other biomolecules. As a result, 
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large amount of composite information is collected via multiple high-throughput and high-content 
technological platforms for molecular profiling in AD which impacts various cellular/molecular 
pathways (15, 27). Since these heterogeneous data need to be integrated in an effective way, 
systems biology strategies are triggering the combined exploration of multiple interacting 
biochemical and genetic pathways and are providing the full depiction of the complex molecular 
pathogenesis of all forms of AD. This will represent the basis of providing effective targeted drugs 
and therapeutic strategies for AD treatment. Upcoming developments in the study of AD 
heterogeneity will possibly allow clinicians to provide more efficacious and helpful 
pharmacological treatments designated as customized (or “tailored”) – that is to say adapted – to 
the definite profiles of their AD patients. Proteomic information, integrated with data obtained from 
the other omics sciences, can inform a more accurate prediction of the risk of developing the 
disease, its progression as well as severity of symptoms, in a specific individual. This information 
needs to be utilized to “tailor” prevention and therapy to that subject as well as to make informed 
choices regarding lifestyle, screening, and preventative treatments. In order to develop the 
conception of targeted therapeutic strategies in the field of AD, it is necessary to integrate cutting-
edge biomarker technologies and transfertilization from more mature translational research fields – 
such as the areas of oncology and cardiovascular diseases – which satisfy regulatory requirements 
for an accurate, sensitive, and well-validated surrogate marker of specific pathophysiological 
processes and/or clinical outcomes (15).  
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